Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis

To date, no systematic analyses are available assessing concordance of molecular classifications between primary tumors (PT) and matched liver metastases (LM) of metastatic colorectal cancer (mCRC). We investigated concordance between PT and LM for four clinically relevant CRC gene signatures. Twenty‐seven fresh and 55 formalin‐fixed paraffin‐embedded pairs of PT and synchronous LM of untreated mCRC patients were retrospectively collected and classified according to the MSI‐like, BRAF‐like, TGFB activated‐like and the Consensus Molecular Subtypes (CMS) classification. We investigated classification concordance between PT and LM and association of TGFBa‐like and CMS classification with overall survival. Fifty‐one successfully profiled matched pairs were used for analyses. PT and matched LM were highly concordant in terms of BRAF‐like and MSI‐like signatures, (90.2% and 98% concordance, respectively). In contrast, 40% to 70% of PT that were classified as mesenchymal‐like, based on the CMS and the TGFBa‐like signature, respectively, lost this phenotype in their matched LM (60.8% and 76.5% concordance, respectively). This molecular switch was independent of the microenvironment composition. In addition, the significant change in subtypes was observed also by using methods developed to detect cancer cell‐intrinsic subtypes. More importantly, the molecular switch did not influence the survival. PT classified as mesenchymal had worse survival as compared to nonmesenchymal PT (CMS4 vs CMS2, hazard ratio [HR] = 5.2, 95% CI = 1.5‐18.5, P = .0048; TGFBa‐like vs TGFBi‐like, HR = 2.5, 95% CI = 1.1‐5.6, P = .028). The same was not true for LM. Our study highlights that the origin of the tissue may have major consequences for precision medicine in mCRC.

[1]  R. Tollenaar,et al.  Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal content , 2018, Oncotarget.

[2]  Stephanie A. Tammen,et al.  DNA Methylation and Hydroxymethylation in Primary Colon Cancer and Synchronous Hepatic Metastasis , 2018, Front. Genet..

[3]  N. Waddell,et al.  Copy number profiles of paired primary and metastatic colorectal cancers , 2017, Oncotarget.

[4]  Donna Neuberg,et al.  Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer , 2017, Science.

[5]  R. Lothe,et al.  CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models , 2017, Scientific Reports.

[6]  A. Witteveen,et al.  A Computational Workflow Translates a 58-Gene Signature to a Formalin-Fixed, Paraffin-Embedded Sample-Based Companion Diagnostic for Personalized Treatment of the BRAF-Mutation-Like Subtype of Colorectal Cancers , 2017, High-throughput.

[7]  I. B. Borel Rinkes,et al.  Neoadjuvant chemotherapy affects molecular classification of colorectal tumors , 2017, Oncogenesis.

[8]  U. Leser,et al.  DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer , 2017, Nature Communications.

[9]  P. Laurent-Puig,et al.  Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression , 2016, Genome Biology.

[10]  D. Zwijnenburg,et al.  Collagen-rich stroma in aggressive colon tumors induces mesenchymal gene expression and tumor cell invasion , 2016, Oncogene.

[11]  J Ricke,et al.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  A. Witteveen,et al.  Equivalence of MammaPrint array types in clinical trials and diagnostics , 2016, Breast Cancer Research and Treatment.

[13]  Etienne Becht,et al.  Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy , 2016, Clinical Cancer Research.

[14]  Jeffrey S. Morris,et al.  The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.

[15]  Céline Lefebvre,et al.  Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles. , 2015, European journal of cancer.

[16]  G. Inghirami,et al.  Stromal contribution to the colorectal cancer transcriptome , 2015, Nature Genetics.

[17]  Camille Stephan-Otto Attolini,et al.  Stromal gene expression defines poor-prognosis subtypes in colorectal cancer , 2015, Nature Genetics.

[18]  Andreas Schlicker,et al.  Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition , 2013, International journal of cancer.

[19]  R. Bernards,et al.  MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling , 2012, Cell.

[20]  Sabine Tejpar,et al.  A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency# , 2012, The Journal of pathology.

[21]  A. Viale,et al.  Comparative genomic analysis of primary versus metastatic colorectal carcinomas. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Victor Moreno,et al.  A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction , 2012, Gut.

[23]  Sabine Tejpar,et al.  Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Yi Guo,et al.  DNA Methylation Profiles of Primary Colorectal Carcinoma and Matched Liver Metastasis , 2011, PloS one.

[25]  E. U. Cidon,et al.  Clinical Medicine Insights: Oncology the Challenge of Metastatic Colorectal Cancer Background , 2022 .

[26]  G. Martinelli,et al.  Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice , 2008, British Journal of Cancer.

[27]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[28]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[29]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.